Journal of Clinical Pharmacy and Therapeutics最新文献

{"title":"Investigation of the Potential Targets and Mechanism Actions of Berberine in the Treatment of Pulpitis Based on Bioinformatics Analysis","authors":"Bingchang Xin,&nbsp;Jia Song,&nbsp;Juan Zhou,&nbsp;Ran Li,&nbsp;Ke Sun,&nbsp;Jin Zhang,&nbsp;Jiaying Wang","doi":"10.1155/2024/1595240","DOIUrl":"10.1155/2024/1595240","url":null,"abstract":"<p>Berberine, an active compound extracted from the Chinese herb, was reported to have an antibacterial effect and an anti-inflammatory effect and promote osteogenic differentiation of human dental pulp stem cells. However, the underlying therapeutic mechanism of berberine in pulpitis is still unknown. Here, bioinformatics analysis was performed to investigate the potential mechanism of berberine against pulpitis. First, we identified the collective targets of berberine and pulpitis from several databases using a Venny online tool. The pattern of interaction between berberine and the targeted protein was visualized by molecular docking. Moreover, we performed GSEA, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses to obtain potential pathways. Cell experiments were performed to validate the bioinformatics analysis results. Prostaglandin-endoperoxide synthase 2 (PTGS2) was identified as the crucial antipulpitis target of berberine via the CytoHubba plugin. Docking analysis indicated that berberine could fit in the binding pocket of the PTGS2 protein. Additionally, berberine exerted its therapeutic effects against pulpitis via multiple pathways. Overall, berberine possessed therapeutic effects against pulpitis through the inactivation of toll-like receptor and NOD-like receptor signaling pathways. The present research proposes a novel approach to explore the therapeutic mechanism of natural products.</p>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2024 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139616541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Hetrombopag for Thrombocytopenia in Patients with Advanced Solid Tumors: A Retrospective Study","authors":"Haonan Liu,&nbsp;Xiao Ma,&nbsp;Di Pan,&nbsp;Menghan Cao,&nbsp;Zhengxiang Han,&nbsp;Hongmei Wang","doi":"10.1155/2023/2859670","DOIUrl":"10.1155/2023/2859670","url":null,"abstract":"<div>\u0000 <p><i>Objective</i>. To analyze and evaluate the clinical value of hetrombopag in cancer therapy-induced thrombocytopenia (CTIT) caused by antitumor therapy for malignant tumors and to provide scientific evidence support for clinical application in the real-world setting. <i>Methods</i>. The clinical data of CTIT patients with advanced solid tumors who received hetrombopag were analyzed retrospectively. The proportion of patients with different characteristics who recovered platelet count to ≥75 × 109/L at day 14 and the effective rate of platelet elevation was compared by the <i>χ</i>² test or Fisher exact probability method. <i>P</i> &lt; 0.05 was considered statistically significant. <i>Results</i>. A total of 60 CTIT patients who received hetrombopag at our site from July 2021 to October 2022 were finally included in this study. The proportion of patients who achieved therapeutic effect within (7 ± 2) days after treatment was 26.7% (16/60), among which 20.0% (12/60) patients had platelet count recovered to ≥100 × 109/L, and 25.0% (15/60) patients had platelet count increase from baseline ≥50 × 109/L. Within (14 ± 2) days of treatment with hetrombopag, 66.7% (40/60) of patients achieved treatment response, of whom 56.7% (34/60) had platelet counts ≥100 × 109/L and 53.3% (32/60) had platelet counts ≥50 × 109/L increase from baseline. In addition, no treatment-related adverse events occurred during the treatment period. <i>Conclusion</i>. This retrospective study provides preliminary evidence that hetrombopag increases platelets in CTIT patients receiving antitumor therapy for advanced solid tumors.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2023 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/2859670","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139138811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights from the Analysis of the Sepsis Dataset: Understanding the Immune Dynamics and Molecular Pathways in Sepsis","authors":"Wenyan Dai,&nbsp;Juan Liu,&nbsp;Xiaoqiang Li","doi":"10.1155/2023/7069469","DOIUrl":"https://doi.org/10.1155/2023/7069469","url":null,"abstract":"<div>\u0000 <p>Sepsis, a critical medical condition instigated by infections, profoundly alters molecular and cellular immune responses. This study focused on the GSE54514 dataset obtained from the GEO database to uncover the complex gene expression patterns and related pathways in sepsis. A total of 42 genes were found to be expressed differently in septic patients compared to those of healthy individuals. The enrichment analyses of pathways revealed the disruption of natural immune pathways such as toll-like receptor signaling, regulation of actin cytoskeleton, and NOD-like receptor signaling. Through ssGSEA analysis, we revealed a strong association between sepsis and immune cell dynamics, finding significant correlations with HLA-related genes and distinct immune cell populations. Furthermore, genes such as CCL5, CD274, CD3E, and CD8A were linked with pathways, notably the “ribosome” pathway, suggesting potential roles in sepsis-related immune responses. The extensive examination provides fresh perspectives on the gene expression and pathway changes in sepsis, laying the groundwork for upcoming therapeutic interventions and a more profound comprehension of this intricate condition.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2023 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/7069469","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143253658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Trastuzumab Combined with Pertuzumab for Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer: A Meta-Analysis Study of Randomized Control Trials","authors":"Qingdong Gao,&nbsp;Xufang Duan","doi":"10.1155/2023/2274965","DOIUrl":"10.1155/2023/2274965","url":null,"abstract":"<div>\u0000 <p><i>Objective</i>. This systematic review was aimed to evaluate the efficacy and safety of trastuzumab in combination with pertuzumab for human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC). <i>Methods</i>. A comprehensive search of PubMed, Web of Science, Embase, China National Knowledge Internet, and Wanfang databases was conducted. All randomized controlled trials on trastuzumab in combination with pertuzumab for HER2-positive BC from the time of database construction to October 2022 were included. A meta-analysis of the included literature was performed using STATA 17.0 software. <i>Results</i>. A total of 8 studies were included, involving a total of 7628 patients, including 3814 patients in the treatment group and 3814 patients in the control groups. The results of the meta-analysis showed that the median progression-free survival was much shorter in the treatment group (trastuzumab combined with pertuzumab) than in the control group (placebo) (OR = 0.656, 95% CI (0.581, 0.741), <i>P</i> &lt; 0.001) and that patients in the treatment group experienced significantly more cases of diarrhea than those in the control group (OR = 2.429, 95% CI (2.065, 2.856), <i>P</i> &lt; 0.001) while experiencing significantly less cases of constipation (OR = 0.641, 95% CI (0.473, 0.869), <i>P</i> = 0.004). Notably, the incidence of nausea and vomiting did not differ significantly between the two groups. In addition, there was no significant difference between the two groups in the incidence of systemic adverse effects such as neutropenia, fatigue, myalgia, and cardiac disease (<i>P</i> &gt; 0.05). However, the treatment group had a much higher incidence of rash than the control group (OR = 1.915, 95% CI (1.505, 2.437), <i>P</i> &lt; 0.001). The risk of serious adverse reactions was markedly higher in patients in the treatment group than that in the control group (OR = 1.342, 95% CI (1.206, 1.494), <i>P</i> &lt; 0.001). <i>Conclusion</i>. The combination of trastuzumab and pertuzumab was not effective in improving the intermediate progression-free survival of patients. However, adverse effects, including diarrhea and rash, are the limiting factors for the current promotion of this combination method.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2023 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/2274965","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139006705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Meta-Analysis for Comparing the Effects of Febuxostat and Allopurinol on Kidney Function in Hyperuricemia Patients Complicated with Chronic Kidney Disease","authors":"Yu Wang,&nbsp;Kai Chen,&nbsp;Su-ya Zhou,&nbsp;Zi-xuan Qiao,&nbsp;Xiao-rong Bao","doi":"10.1155/2023/9946667","DOIUrl":"10.1155/2023/9946667","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. This study was designed to assess the effects of febuxostat on the uric acid level and kidney function of hyperuricemia (HUA) patients complicated with chronic kidney disease (CKD). <i>Methods</i>. A computer-based search was conducted on the China National Knowledge Infrastructure (CNKI), Wanfang, PubMed, and Web of Science databases from the inception of the databases to April 2023 to identify clinical randomized controlled trials on HUA and CKD, with comparisons between febuxostat and allopurinol as variables of interest. The meta-analysis was conducted using Stata v17.0. <i>Results</i>. Eighteen studies were included in this meta-analysis, encompassing a total of 1877 patients. These patients were segregated into a control group (treated with allopurinol or placebo) consisting of 1039 individuals and an experimental group (treated with febuxostat alone or a combination of febuxostat with other therapies) comprising 838 patients. The meta-analysis revealed that patients in the experimental group, treated with febuxostat, exhibited a significantly higher estimated glomerular filtration rate (eGFR) than those in the control group treated with allopurinol (weighted mean difference (WMD): 2.897, 95% CI: 1.336 to 4.458, <i>P</i> &lt; 0.001). In addition, the experimental group demonstrated significantly lower levels of serum creatinine (WMD: −17.810, 95% CI: −24.147 to −11.474, <i>P</i> &lt; 0.001), serum uric acid (WMD: −91.891, 95% CI: −117.609 to −66.173, <i>P</i> &lt; 0.001), and blood urea nitrogen (WMD: −1.284, 95% CI: −1.837 to −0.731, <i>P</i> &lt; 0.001). However, there was no significant difference in 24-hour urinary protein quantity (WMD: −0.198, 95% CI: −0.413 to 0.016, <i>P</i> = 0.070) between the two groups. <i>Conclusion</i>. These findings suggest that febuxostat may offer a more beneficial therapeutic option for managing CKD in hyperuricemic patients. However, the observed heterogeneity and the limited diversity of the study population warrant cautious interpretation of these results.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2023 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/9946667","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138977119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydrogel-Loaded Exosomes: A Promising Therapeutic Strategy for Musculoskeletal Disorders","authors":"Chunyu Zhang,&nbsp;Xuchang Zhou,&nbsp;Dongxue Wang,&nbsp;Li Hao,&nbsp;Zhipeng Zeng,&nbsp;Lei Su","doi":"10.1155/2023/1105664","DOIUrl":"10.1155/2023/1105664","url":null,"abstract":"<div>\u0000 <p>Clinical treatment strategies for musculoskeletal disorders have been a hot research topic. Accumulating evidence suggests that hydrogels loaded with MSC-derived EVs show great potential in improving musculoskeletal injuries. The ideal hydrogels should be capable of promoting the development of new tissues and simulating the characteristics of target tissues, with the properties matching the cell-matrix constituents of autologous tissues. Although there have been numerous reports of hydrogels loaded with MSC-derived EVs for the repair of musculoskeletal injuries, such as intervertebral disc injury, tendinopathy, bone fractures, and cartilage injuries, there are still many hurdles to overcome before the clinical application of modified hydrogels. In this review, we focus on the advantages of the isolation technique of EVs in combination with different types of hydrogels. In this context, the efficacy of hydrogels loaded with MSC-derived EVs in different musculoskeletal injuries is discussed in detail to provide a reference for the future application of hydrogels loaded with MSC-derived EVs in the clinical treatment of musculoskeletal injuries.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2023 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/1105664","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136281639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preparation and Evaluation of Onjisaponin B-Loaded Liposomes for Drug Delivery to Enhance Mitochondrial Function and Rescue Parkinson’s Disease by Activating Mitophagy","authors":"Junhua Zhang,&nbsp;Rui Bao,&nbsp;Faisal Raza,&nbsp;Hajra Zafar,&nbsp;Yingjie Qi,&nbsp;Yurui Geng,&nbsp;Ran Li,&nbsp;Jianqin Xue,&nbsp;Feng Shi","doi":"10.1155/2023/1262109","DOIUrl":"10.1155/2023/1262109","url":null,"abstract":"<div>\u0000 <p>Onjisaponin B (OB) is the main active ingredient of Radix Polygalae with various bioactivities. However, the protective effect of OB in Parkinson’s disease (PD) has not been fully studied. Liposomes are ideal nanocarriers for drugs targeting the brain. In this study, we investigated the therapeutic effect of OB-loaded liposomes (lip OB) on a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- (MPTP-) induced mouse model of PD and 1-methyl-4-phenylpyridinium- (MPP⁺-) induced cell model of PD. Our results showed that lip OB significantly ameliorated MPTP-induced motor deficits and dopaminergic neuron loss in vivo and prevented MPP⁺-triggered cell viability reduction and apoptosis in vitro. Lip OB also improved mitochondrial dysfunction in PD models by driving PINK1/Parkin-mediated mitophagy. Furthermore, silencing PINK1 compromised the beneficial effects of lip OB on MPP⁺-treated PC12 cells. These findings suggested lip OB mitigates Parkinsonism in vivo and in vitro by enhancing mitochondrial dysfunction through the PINK1/Parkin pathway of mitophagy, which provides a new possibility for treating PD.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2023 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/1262109","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135341259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Real-World Safety Analysis of Upadacitinib Based on FDA Adverse Event Reporting System (FAERS)","authors":"Yazheng Zhao,&nbsp;Qian Cheng,&nbsp;Shupeng Zou,&nbsp;Xuan Shi,&nbsp;Mengling Ouyang,&nbsp;Minghui Sun","doi":"10.1155/2023/8000874","DOIUrl":"10.1155/2023/8000874","url":null,"abstract":"<div>\u0000 <p><i>Objectives</i>. To investigate adverse events (AEs) associated with upadacitinib in the real world using data mining from the FDA Adverse Event Reporting System (FAERS). <i>Methods</i>. Disproportionality analysis, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multiitem gamma Poisson shrinker (MGPS) algorithms, was used to quantify the signals of upadacitinib-associated AEs. <i>Results</i>. The study found 23683 reports of AEs associated with upadacitinib. A total of 149 substantial disproportionality preferred terms (PTs) that complied with all algorithms were identified. The infections discovered matched those mentioned in the specification and clinical trials, including pneumonia, upper respiratory tract infection, herpes zoster, and acne. Malignant and thrombotic AEs were also noted. Diverticulitis, myocardial infarction, transient ischaemic attack, and dysstasia were among the new AEs found. Upadacitinib-related AEs had a median onset time of 237 days and an interquartile range (IQR) of 78–509 days. <i>Conclusions</i>. The findings of our study were in line with clinical observations, and we also identified potential novel and unexpected AEs signals for upadacitinib, indicating the necessity for prospective clinical trials to corroborate these findings and demonstrate their link. Our results offered significant support for additional upadacitinib safety research.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2023 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/8000874","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135933175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Poor Correlation of Rivaroxaban Concentration with the Routine Coagulation Screening Test in Chinese Patients with Atrial Fibrillation","authors":"Jiake He,&nbsp;Bo Zhu,&nbsp;Yang Shen,&nbsp;Jianping Hu,&nbsp;Kui Hong","doi":"10.1155/2023/9962812","DOIUrl":"10.1155/2023/9962812","url":null,"abstract":"<div>\u0000 <p><i>Aims</i>. The aim of this study is to assess the relationship between rivaroxaban plasma concentration quantified by the gold standard and anticoagulant activities measured by routine coagulation assays in Chinese atrial fibrillation (AF) patients. Whether the normal results of these tests were reliable to rule out clinically relevant rivaroxaban levels at various thresholds was also explored. The effect of clinical drug-drug interactions (DDIs) on the exposure and anticoagulant effect of rivaroxaban were further evaluated. <i>Methods</i>. 116 patients receiving rivaroxaban for the management of nonvalvular AF were recruited. Rivaroxaban concentrations and coagulation tests were measured by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and a blood coagulation analyzer, respectively. <i>Results</i>. The correlation of trough concentration (<i>C</i>_trough) and prothrombin time (PT) or international normalized ratio (INR) was moderate with Spearman’s correlation coefficient of 0.495 and 0.506, respectively. A normal PT/INR was unable to rule out <i>C</i>_trough levels of &gt;30 ng/mL and &gt;50 ng/mL, but the negative predictive value reached 100% to exclude <i>C</i>_trough of &gt;100 ng/mL. <i>C</i>_trough showed a small correlation with activated partial thromboplastin time (aPTT) (Spearman’s correlation coefficient: 0.241) and no correlation with thrombin time (TT) (Spearman’s correlation coefficient: 0.074). Neither aPTT nor TT accurately predicted <i>C</i>_trough at any concentration. Peak concentration (<i>C</i>_peak) did not correlate with any coagulation parameters. The presence of digoxin and febuxostat significantly increased rivaroxaban <i>C</i>_trough by 2.18 fold and prolonged PT and INR by 44.16% and 43.60%, respectively. <i>Conclusions</i>. Normal routine coagulation assays were insufficient to monitor therapy with rivaroxaban. Poor correlations between rivaroxaban concentration and routine coagulation assays were observed in Chinese AF patients. The use of digoxin/febuxostat alone had no effect on rivaroxaban concentrations; however, combined strong breast cancer resistance protein inhibitor (febuxostat) and P-glycoprotein probe (digoxin) in patients with renal impairment is likely to cause clinically significant DDI with rivaroxaban. More studies are needed to establish routine therapeutic drug monitoring of rivaroxaban in clinical practice.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2023 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/9962812","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135871991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuromuscular Blocking Agents and Cancer: A Narrative Review","authors":"Rui Chen,&nbsp;Yan Sun,&nbsp;Yufan Li,&nbsp;Xiaoke Dou,&nbsp;Maosha Dai,&nbsp;Shujun Sun,&nbsp;Yun Lin","doi":"10.1155/2023/5607134","DOIUrl":"10.1155/2023/5607134","url":null,"abstract":"<div>\u0000 <p><i>Objective</i>. Neuromuscular blocking agents (NMBAs) are part of the three elements of general anaesthesia (sedation, analgesia, and muscle relaxation), which can relax muscles and facilitate intubation and surgery. It has been reported that cancer cells are prone to invasion or metastasis during surgery, but various anaesthetics are currently used in cancer resection, particularly NMBA, and the effects on cancer cell behavior are poorly understood. Guidelines for the correct application of NMBA in cancer surgery have not been reported; therefore, the aim of this paper is to explore the relationship between NMBA and cancer. <i>Methods</i>. Two investigators independently searched PubMed, Embase, the Cochrane Library, Web of Science, and CBM for articles of NMBA and cancer. <i>Results</i>. The available evidence suggests that cisatracurium may be more appropriate for use in anaesthesia for cancer surgery, while rocuronium deserves further attention, particularly for breast and gastric cancer surgery, and vecuronium is suitable for breast cancer and non-small-cell lung cancer, while it is used with caution in gastric cancer. Also, the relationship between NMBA (mivacurium, succinylcholine, gantacurium, and decamethonium bromide) and cancer is unclear and deserves further study. <i>Conclusion</i>. The effect of different NMBAs on cancer cells varies, and the effect of some NMBAs on cancer cells is unclear, and most of the current findings are only from in vitro studies, which need to be validated by further clinical studies in the future to better guide the clinical application of NMBAs.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2023 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/5607134","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135872485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}